# IBD evidence final targeted-remediation completion report

Date: 2026-07-30  
Outcome: ready for one final independent QA; not approved

## Completed scope

Only the remaining QA failures were remediated. Work remained inside `/Users/janakirampulipati/ibd-research-review`; the application repository was not inspected or modified.

No broad research, evidence import, RAG, embeddings, Azure configuration, API changes, UI changes, LangChain, LangGraph, or production work was performed.

## CLM-081 through CLM-086 locator status

All six claims now have verified precise locators:

- CLM-081: Section 3, Statement 1
- CLM-082: Section 4.1, opening paragraph
- CLM-083: Section 4.3.2, Statement 21.1, paragraph 1
- CLM-084: Section 3.8.2.1, Practice Point 2A, sentence 1
- CLM-085: Section 3.8.2.1, Practice Point 2A, sentence 3
- CLM-086: Section 3.8.2.2, Practice Point 2B, sentence 1

The supporting excerpts were preserved. CLM-083’s final wording was narrowed to retain the passage’s no-data, mechanism-based, and obstructive-symptom limitations.

## CLM-097 final disposition

CLM-097 was narrowed to one directly supported assertion: no oral IBD diet can be generally recommended to promote remission in active IBD.

Three unique atomic split claims were created from independently supported ESPEN passages:

- CLM-098: pediatric exclusion-diet recommendation
- CLM-099: adult exclusion-diet recommendation
- CLM-100: long-term effectiveness and possible-risk data limitation

All four final claims cite the official ESPEN PDF, journal page 357, and an exact recommendation or commentary paragraph.

## CLM-092 status

CLM-092 remains `still_needs_evidence`. It is visibly not approval-ready and is excluded from any future approved-data export until the missing evidence is resolved and a human explicitly approves it.

No additional CLM-092 research was performed.

## Claim counts

- Active claims ready for final independent QA: 60
- Active claims needing more evidence: 1
- Total active claims: 61
- New replacement/split claims created in this run: 3
- Targeted claims removed in this run: 0
- Cumulative original claims removed in the prior remediation: 37

The original 95-claim accounting remains unchanged. The active-row increase reflects only the atomic split of CLM-097.

## Workbook delivered

`ibd-evidence-review-final-remediation.xlsx` contains exactly:

1. Sources
2. Claims
3. Locator Corrections
4. CLM-097 Remediation
5. Unresolved Claims
6. Removed or Replaced Claims
7. Validation Summary
8. Final Remediation Summary

All eight sheets were rendered and visually inspected. Headers, wrapped evidence text, status highlighting, yellow human-input fields, summary formulas, and audit trails are visible and legible. No formula-error matches were found.

## Tests

Command:

`PYTHONPATH=. .venv/bin/pytest -q`

Result:

- Passed: 67
- Failed: 0

Focused tests cover ECCO locator precision, authoritative-capture integrity, CLM-083 narrowing, CLM-097 atomicity and direct support, unique split IDs, CLM-092 export exclusion, active-source validity, active-claim count reconciliation, generic-locator exclusion, blank reviewer fields, exact workbook sheets, formula scanning, and all-sheet visual validation.

## Unresolved limitations

- CLM-092 remains unresolved and excluded.
- Public source access does not establish downstream reuse or republication rights.
- This package has not yet passed the requested final independent QA.
- All human-review decision and note fields remain blank.
- No source or claim is approved.

## Hard stop

Stop here for one final independent QA. Do not approve or import evidence and do not perform application, RAG, Azure, API, or UI work.
